Cargando…

Etrolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease: An Overview of the Phase 3 Clinical Program

INTRODUCTION: Etrolizumab is a next-generation anti-integrin with dual action that targets two pathways of inflammation in the gut. A robust phase 3 clinical program in ulcerative colitis (UC) and Crohn’s disease is ongoing and will evaluate the efficacy and safety of etrolizumab in well-defined pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sandborn, William J., Vermeire, Severine, Tyrrell, Helen, Hassanali, Azra, Lacey, Stuart, Tole, Swati, Tatro, Amanda R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467434/ https://www.ncbi.nlm.nih.gov/pubmed/32445184 http://dx.doi.org/10.1007/s12325-020-01366-2

Ejemplares similares

An Open-Label Tolerability and Actual-Use Human Factors Study of Etrolizumab Autoinjector in Healthy Volunteers
por: Tyrrell, Helen, et al.
Publicado: (2021)

Exposure‐response relationships of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis
por: Kassir, Nastya, et al.
Publicado: (2022)

Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis
por: Moein, Anita, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial
por: Zhang, Wenhui, et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis
por: Wei, Xiaohui, et al.
Publicado: (2017)

Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial
por: Zhang, Wenhui, et al.
Publicado: (2022)

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
por: Rutgeerts, Paul J, et al.
Publicado: (2013)

Assessment of Disease‐Related Therapeutic Protein Drug‐Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis
por: Wei, Xiaohui, et al.
Publicado: (2016)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis
por: Dulai, Parambir S., et al.
Publicado: (2020)

Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program
por: Sandborn, William J., et al.
Publicado: (2022)

Infliximab: the evidence for its place in therapy in ulcerative colitis
por: Van Assche, Gert, et al.
Publicado: (2007)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy Volunteers
por: Zhang, Wenhui, et al.
Publicado: (2021)

Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease
por: Lichnog, Charlotte, et al.
Publicado: (2019)

Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials
por: Hanauer, Stephen, et al.
Publicado: (2019)

Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial
por: Vermeire, Séverine, et al.
Publicado: (2020)

Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis
por: Vermeire, Séverine, et al.
Publicado: (2020)

Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study
por: Loftus, Edward V, et al.
Publicado: (2022)

Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study
por: Vermeire, Séverine, et al.
Publicado: (2021)

Genetic Variation in the Familial Mediterranean Fever Gene (MEFV) and Risk for Crohn's Disease and Ulcerative Colitis
por: Villani, Alexandra-Chloé, et al.
Publicado: (2009)

Crohn's disease and ulcerative colitis Surgical management
por: Wilkinson, A J
Publicado: (1996)

Mucosal Barrier in Ulcerative Colitis and Crohn's Disease
por: Dorofeyev, A. E., et al.
Publicado: (2013)

Ulcerative Colitis and Crohn's Disease: Similarities and Distinctions
por: Sawyerr, Af M, et al.
Publicado: (1994)

Review of pregnancy in Crohn’s disease and ulcerative colitis
por: Laube, Robyn, et al.
Publicado: (2021)

Adherence in ulcerative colitis: an overview
por: Testa, Anna, et al.
Publicado: (2017)

Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials
por: Feagan, Brian G., et al.
Publicado: (2021)

Fecal S100A12 levels measured by a new ELISA are increased in ulcerative colitis (UC) and Crohn’s disease (CD) and correlates with intestinal damage
por: Garnero, P, et al.
Publicado: (2010)

Adalimumab in Crohn’s disease
por: Van Assche, Gert, et al.
Publicado: (2007)

Expressing the Differences between Crohn Disease and Ulcerative Colitis
por: Wijmenga, Cisca
Publicado: (2005)

Carbohydrate Intake in the Etiology of Crohn's Disease and Ulcerative Colitis
por: Chan, Simon S. M., et al.
Publicado: (2014)

The Changing Prognosis of Ulcerative Colitis and Crohn Disease by Decades
por: Korelitz, Burton I, et al.
Publicado: (2021)

Diagnosis of Crohn’s disease and ulcerative colitis using the microbiome
por: Kang, Da-Yeon, et al.
Publicado: (2023)

Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study
por: Cleynen, Isabelle, et al.
Publicado: (2016)

Plasma microRNA Profile Differentiates Crohn’s Colitis From Ulcerative Colitis
por: Netz, Uri, et al.
Publicado: (2018)

Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative Colitis
por: Lee, Ho-Su, et al.
Publicado: (2020)

Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)

Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
por: Gilroy, Leah, et al.
Publicado: (2014)

Gastritis Associated with Initially Pediatric Crohn's Disease and Ulcerative Colitis
por: Basturk, Ahmet, et al.
Publicado: (2018)

Crohn’s Disease and Ulcerative Colitis Show Unique Cytokine Profiles
por: Nemeth, Zoltan H, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_45hhqrjv8ej26bhcergn6m6tt0